SNWV (SANUWAVE Health) EBIT: $21.08 Mil (TTM As of Mar. 2026)


SNWV SANUWAVE Health Inc SNWV
38 GF Score
Price $8.57
GF Value $11.86
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is SANUWAVE Health EBIT?

SANUWAVE Health SNWV +4.39% 38 EBIT is $21.08 Mil as of Mar. 2026. GuruFocus rates SNWV with a GF Score™ of 38/100 and a GF Value™ of $11.86 (Modestly Undervalued). The stock has 8 warning signs investors should review.

SANUWAVE Health's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-0.89 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $21.08 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. SANUWAVE Health's annualized ROC % for the quarter that ended in Mar. 2026 was -22.15%. SANUWAVE Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -107.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. SANUWAVE Health's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 24.77%.


SANUWAVE Health  (NAS:SNWV) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

SANUWAVE Health's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-4.496 * ( 1 - 0% )/( (20.126 + 20.479)/ 2 )
=-4.496/20.3025
=-22.15 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

SANUWAVE Health's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.572/( ( (2.362 + max(0.616, 0)) + (2.904 + max(0.758, 0)) )/ 2 )
=-3.572/( ( 2.978 + 3.662 )/ 2 )
=-3.572/3.32
=-107.59 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.422 + 5.934 + 1.312) - (10.437 + 0.388 + 1.227)
=0.616

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6 + 5.903 + 1.274) - (10.966 + 0.487 + 0.966)
=0.758

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

SANUWAVE Health's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=21.076/85.078
=24.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SANUWAVE Health EBIT Related Terms


SANUWAVE Health EBIT Historical Data

* Premium members only.

The historical data trend for SANUWAVE Health's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SANUWAVE Health EBIT Chart

SANUWAVE Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.14 3.84 -10.18 -19.28 18.15

SANUWAVE Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.21 2.93 12.05 6.99 -0.89

SNWV vs QTRX, CVRX, NNOX: EBIT Comparison

For the Medical Devices subindustry, SANUWAVE Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SANUWAVE Health EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SANUWAVE Health's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SANUWAVE Health's EV-to-EBIT falls into.


SNWV
38GF Score
SANUWAVE Health Inc SNWV
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SANUWAVE Health EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $21.08 Mil mean?
SANUWAVE Health (SNWV) has a EBIT of $21.08 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on SANUWAVE Health.
Is SANUWAVE Health's EBIT too high?
SANUWAVE Health's current EBIT is $21.08 Mil. Overall, SANUWAVE Health has a GF Score™ of 38/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SANUWAVE Health's EBIT compare to QTRX and CVRX?
SANUWAVE Health's EBIT of $21.08 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on SANUWAVE Health. SANUWAVE Health's current EBIT is $21.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SANUWAVE Health stock overvalued right now?
Based on GuruFocus' analysis, SANUWAVE Health (SNWV) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.86, compared to a current price of $8.57 — trading 27.7% below its estimated fair value. The current EBIT is $21.08 Mil. SANUWAVE Health's overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For SANUWAVE Health (SNWV), the current EBIT is $21.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SANUWAVE Health (SNWV) Overvalued in 2026?

Based on GuruFocus' analysis, SANUWAVE Health stock appears to be undervalued. The current stock price of $8.57 is trading 27.7% below its estimated GF Value™ of $11.86. GuruFocus considers SANUWAVE Health to be Modestly Undervalued.

Key valuation signals for SNWV:

  • EBIT: $21.08 Mil
  • GF Value™: $11.86 vs. price of $8.57 (27.7% below fair value)
  • GF Score™: 38/100 with 8 warning signs

No single metric tells the full story. See the SNWV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


SANUWAVE Health Business Description

Address 9600 W. 76th Street, Suite 118, Eden Prairie, MN, USA, 55344
SANUWAVE Health Inc is a medical device company providing directed energy products into the wound care space. It is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. Sanuwave's patented, FDA-cleared, and commercialised product is the UltraMIST system, which is used to treat a variety of acute and chronic wounds using ultrasound technology. The company operates in one reportable segment, the design and sale of medical devices. Geographically, the company generates revenue mainly from the United States.
38GF Score

Get the complete analysis for SNWV

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.57
Price
$11.86
GF Value